Health
Ontario Pioneers Access to Treatment for Severe Alopecia Areata with Lilly's Olumiant®
Eli Lilly Canada Inc. ("Lilly") announced today that Ontario leads the way as the first province to add Olumiant® for severe alopecia areata to its public drug formulary—the first and only treatment for adult patients with severe alopecia areata available through public coverage.
About this update from Eli Lilly And Company
[{"type":"text","content":"TORONTO, Jan. 14, 2026 /CNW/ - Eli Lilly Canada Inc. ("Lilly") announced today that Ontario leads the way as the first province to add Olumiant® for severe alopecia areata to its public drug formulary—the first and only treatment for adult patients with severe alopecia areata available through public coverage.","length":326,"tagName":"p"},{"type":"image","alt":"Lilly Canada (CNW Group/Eli Lilly Canada Inc.)","displaySize":"","headline":null,"caption":"Lilly Canada (CNW Group/Eli Lilly Canada Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":375,"height":204,"url":"https://media.zenfs.com/en/cnwgroup.com/947b60ce205f1931a0aa62c5e816eb95"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/opkzu5VYF48xgUVAZZ2hOw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM4NDtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/947b60ce205f1931a0aa62c5e816eb95","width":375,"height":204}},"href":"https://mma.prnewswire.com/media/2861244/Eli_Lilly_Canada_Inc__Ontario_Pioneers_Access_to_Treatment_for_S.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We applaud Ontario for taking the lead in giving people with alopecia areata access to an effective treatment option, Olumiant," said Mathilde Merlet, President and General Manager of Lilly Canada. "Olumiant is the first and only oral medicine approved for severe alopecia areata with a Letter of Intent from the pan-Canadian Pharmaceutical Alliance (pCPA), so we encourage all public drug plans to move quickly so patients who have been waiting for a solution to this immune-related condition can get the care they need."","length":543,"tagName":"p"},{"type":"text","content":"The use of Olumiant (baricitinib) for adult patients with severe AA was authorized by Health Canada on January 26, 2024. The approval of Olumiant (baricitinib) for severe alopecia areata was based on Lilly's BRAVE-AA1 and BRAVE-AA2 Phase 3 clinical trials, evaluating the efficacy and safety of Olumiant in 1,200 adult patients with severe AA (≥50% scalp hair loss as defined by a Severity of Alopecia Tool [SALT] score ≥50).1 ","length":435,"tagName":"p"},{"type":"text","content":"On October 2, 2024, Canada's Drug Agency- L'Agence des medicaments du Canada (CDA-AMC) issued a positive final recommendation of reimbursement with conditions for Olu...